Modulation of the arsenic effects on cytotoxicity, viability, and cell cycle in porcine endothelial cells by selenium.
D000818:Animals; D017209:Apoptosis / Q000187:drug effects* / Q000502:physiology; D001149:Arsenates / Q000633:toxicity; D001151:Arsenic / Q000633:toxicity*; D000077237:Arsenic Trioxide; D001152:Arsenicals; D018053:Arsenites / Q000633:toxicity; D053148:Caspase 3; D020169:Caspases / Q000187:drug effects / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects / Q000502:physiology; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D002478:Cells, Cultured; D003603:Cytotoxins / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions / Q000502:physiology; D042783:Endothelial Cells / Q000187:drug effects* / Q000378:metabolism; D005979:Glutathione Peroxidase / Q000187:drug effects / Q000378:metabolism; D007399:Interphase / Q000187:drug effects / Q000502:physiology; D009336:Necrosis; D010087:Oxides / Q000633:toxicity; D012643:Selenium / Q000494:pharmacology*; D017670:Sodium Compounds / Q000633:toxicity; D034421:Sus scrofa; D016159:Tumor Suppressor Protein p53 / Q000187:drug effects / Q000378:metabolism
D001149:Arsenates; D001152:Arsenicals; D018053:Arsenites; D003603:Cytotoxins; D010087:Oxides; D017670:Sodium Compounds; D016159:Tumor Suppressor Protein p53; C017947:sodium arsenite; C009277:sodium arsenate; D005979:Glutathione Peroxidase; D053148:Caspase 3; D020169:Caspases; D012643:Selenium; D001151:Arsenic; D000077237:Arsenic Trioxide